Clinical trial NCT05526664: Omics Gaucher Study: Multiomic Approach
Official title: Omics Gaucher Study: Multiomic Approach to Describe the Gaucher Disease Treatment Dynamics in Comparison to Untreated Healthy Volunteers
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Gaucher Disease
Lead sponsor: CENTOGENE GmbH Rostock
Sponsor class: INDUSTRY
First posted: 2022-09-02
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Gaucher participants diagnosed with Type 1 and Type 3. Healthy volunteers.

Brief summary: The study aims to investigate the transcriptomic and metabolomic changes in blood, plasma and isolated monocytes from Gaucher patients and healthy controls.

Detailed description: Gaucher disease is one of the most common lysosomal storage disorders (LSD) and is an autosomal recessive inherited disorder, primed by mutation in the GBA1 gene which leads to a deficiency in β-glucocerebrosidase (GCase) activity and accumulation of its substrate glucosylceramide (GluCer)/-sphingosine (GluSph). The macrophages are the main cell type exhibiting a Gaucher disease phenotype. The large accumulation of GluCer and to a lesser extent that of GluSph lead to dysfunction in organs such as spleen, liver, bone marrow, and lungs.

However, a validated, reproducible, and broadly applicable tool to classify Gaucher Disease at any stage of the disease is still missing.

The development of new technologies, such as genomic analysis by next generation sequencing (NGS) and other "omics technologies," has advanced the molecular understanding and diagnosis of Rare Diseases

The current study will analyze the transcriptional and metabolomic profiles in blood, plasma and isolated monocytes from Gaucher patients and healthy controls with the aim to compare these profiles and to define how much a patient profile differs from a healthy one.

Eligibility criteria: Inclusion Criteria:

Gaucher Type 1 participants:

* Informed consent
* The participant is older than 18 years old
* The participant was diagnosed with Gaucher Type 1 disease

Gaucher Type 3 participants:

* Informed consent
* The participant is older than 18 years old
* The participant was diagnosed with Gaucher type 3 disease

Healthy participants:

* Informed consent
* The participant is older than 18 years old
* Healthy participants

Exclusion Criteria:

Gaucher Type I participants:

* The participant had any other clinically significant disease
* The participant had a recent (within 14 days) acute infection and/or vaccination

Gaucher Type 3 participants:

* Diagnosis of a significant CNS disease or cardiovascular disease other than Gaucher type 3
* The participant had a recent (within 14 days) acute infection and/or vaccination

Healthy participants:

* The participant had a recent (within 14 days) acute infection and/or vaccination

Primary outcomes:
measure: OMICS DATA
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Hamburg
country: Germany
facility: UKE
Study officials:
affiliation: CENTOGENE GmbH
name: Peter Bauer, MD
role: PRINCIPAL_INVESTIGATOR
References: